Happenings

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 3 clinical trial testing the investigational gene-editing therapy, nexiguran…

More than half of adults with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), a condition marked by heart damage, also have multi-nerve damage,…

The European Commission has expanded the indication of Amvuttra (vutrisiran) to include adults with ATTR amyloidosis with cardiomyopathy, or heart damage (ATTR-CM…

Kristen Hsu, ARC’s Executive Director of Research, shared the latest updates on ATTR (transthyretin amyloidosis) clinical trials and what these developments mean…

Dr. Sami Khella, Professor of Neurology and co-founder of the Amyloidosis Program at the University of Pennsylvania discussed the latest in diagnosis, treatment,…

This webinar “Coffee Chat” style webinar is your chance to learn about the different programs and projects ARC has been working on in 2025! Hear directly from ARC…

Clinical Psychologist Rosalind Kalb, PhD shared helpful advice, self-care tips, and real-life strategies to make daily life a little easier for both Care Partners…

Sabrina Rebello, ARC’s Senior Research Manager, presented an in-depth overview of key insights from our Annual Community Survey. This webinar focused on…

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently includes Pfizer and BridgeBio and is…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York…